A committee of the European Medicines Agency has recommended marketing authorization for dupilumab (Dupixent) for the treatment of moderate to severe atopic dermatitis in adults who are candidates for systemic therapy.
International Approvals
http://ift.tt/2uiCg0q
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου